A randomized double-blind placebo- and positive-controlled crossover study to evaluate the effects of single doses of SD-809 (deutetrabenazine) and tetrabenazine on the corrected QT interval
Objective: Evaluate the pharmacokinetics and pharmacodynamics (QTc) of SD-809 (deutetrabenazine) and tetrabenazine. Background: SD-809 is a VMAT-2 inhibitor in clinical development for treatment of hyperkinetic…A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome
Objective: This study explored the safety, tolerability and preliminary efficacy of SD-809 (deutetrabenazine) in adolescents with moderate to severe tics associated with Tourette syndrome (TS).…A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD)
Objective: To determine the efficacy and safety of deutetrabenazine (DTB) as a treatment for tardive dyskinesia (TD). Background: There is no approved treatment for TD,…Clinical course and treatment of 6 children with GNAO1 mutations causing a severe, life-threatening chorea
Objective: We describe the clinical course of 6 patients with de novo GNAO1 mutations with severe chorea, developmental delay and hypotonia, but the absence of…Functional motor outcomes after globus pallidus internus deep brain stimulation in Huntington´s disease – A case report
Objective: The aim of this study was to analyse the motor outcome before and after 6 month follow-up in a HD patient treated by GPi-DBS.…Efficacy and safety of tetrabenazine in hyperkinetic movements disorders- An observational study
Objective: To assess the efficacy and side-effects of TBZ in Huntington disease (HD), vascular chorea, tics, dystonia, oromandibular dyskinesia and other tardive syndromes (TS). Background:…Prospective evaluation of pallidal deep brain stimulation in Huntington’s disease
Objective: To prospectively evaluate the effect of bilateral pallidal deep brain stimulation (DBS) on motor symptoms, activities of daily living and quality of life in…Evaluating swallowing function in patients with Huntington disease enrolled in the first-HD study
Objective: The Swallowing Disturbance Questionnaire (SDQ) was administered to patients with Huntington disease (HD) as part of a randomized, controlled study of deutetrabenazine for the…Evaluation of quality of life (QOL), patient- and clinician-reported outcomes with deutetrabenazine treatment of chorea in Huntington disease in first-HD
Objective: To assess if deutetrabenazine treatment of chorea associated with HD resulted in changes in QoL, Patient Global Impression of Change (PGIC), or Clinical Global…